Zolmitriptan
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Zolmitriptan: Atrophoderma vermiculata
One-Sentence Summary
Zolmitriptan is a triptan (5-HT1B/1D receptor agonist) that is already marketed in Australia for acute migraine. Evidence is limited to 0 registered clinical trials and general migraine and triptan literature. None of the supporting literature is specific to brainstem aura.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Atrophoderma vermiculata |
| TxGNN Prediction Score | 0.9990 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for zolmitriptan is not recorded in the data compiled for this report. The published reviews describe it as a selective 5-HT1B/1D agonist that acts on the trigeminovascular system, both peripherally and centrally. It has proven efficacy for acute migraine, with or without aura.
Migraine with brainstem aura is a subtype of migraine, so the same trigeminovascular mechanism could plausibly apply. This is the likely basis for the high model score.
There is an important caveat. Triptans have historically been used cautiously in brainstem aura (basilar-type) migraine because of theoretical concerns about vasoconstriction. The available literature consists of general migraine and triptan reviews and guidelines. It contains no study that directly supports or refutes zolmitriptan use in this subtype. The prediction is therefore a hypothesis to test, not a ready-to-use new indication.
Clinical Trial Evidence
Currently no related clinical trials registered for migraine with brainstem aura.
Literature Evidence
None of the publications below studies brainstem aura directly. They are the closest available evidence on migraine and triptans in general.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25600718 | 2015 | Review / evidence assessment | Headache | American Headache Society update on the evidence for acute migraine drugs |
| 22644173 | 2012 | RCT subgroup analysis | Neurol Sci | Frovatriptan vs zolmitriptan 2.5 mg in migraine with aura. Only 18 patients, so the findings are limited |
| 25916333 | 2015 | Meta-analysis | J Headache Pain | Frovatriptan compared with rizatriptan, zolmitriptan and almotriptan in migraine with aura. Triptans are probably not effective if taken during the aura phase |
| 12083998 | 2002 | Review | Expert Opin Pharmacother | Randomised placebo-controlled trials show zolmitriptan 2.5 and 5 mg is effective, with onset within 45 minutes |
| 10473025 | 1999 | Review | Drugs | Zolmitriptan is a selective 5-HT1B/1D agonist, effective and well tolerated in moderate to severe migraine |
| 9399012 | 1997 | Preclinical pharmacology | Cephalalgia | Zolmitriptan inhibits trigeminovascular activation both centrally and peripherally in preclinical models |
| 12864759 | 2003 | Clinical study | Headache | Transcranial Doppler blood flow changes during migraine attacks treated with zolmitriptan or sumatriptan |
| 17177580 | 2007 | Post-marketing surveillance | Clin Drug Investig | Real-life effectiveness and satisfaction with zolmitriptan 5 mg nasal spray |
| 21028917 | 2010 | Review | Paediatr Drugs | Use of triptans for paediatric migraine |
| 22298171 | 2012 | Case report | Cardiol J | Case of acute myocardial infarction after zolmitriptan, relevant to cardiovascular safety |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 8266C | Zomig | Tablet 2.5 mg (oral) | Indication text not listed in the data compiled for this report |
Safety Considerations
Product Information warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for label safety information. The items below come from the knowledge graph and interaction databases, not from label text.
- Contraindication signals (knowledge graph): These include:
- hypertension
- coronary artery disease, myocardial infarction and myocardial ischaemia
- Prinzmetal angina
- stroke, transient ischaemic attack, cerebral infarction and other cerebrovascular disorders
- vertebrobasilar insufficiency
- peripheral vascular disease and Raynaud disease
- ischaemic bowel disease
- Wolff-Parkinson-White syndrome
- familial or sporadic hemiplegic migraine
- kidney, liver and gallbladder disease
- hemoglobinopathy
- Relevance to brainstem aura: Vertebrobasilar insufficiency and hemiplegic migraine appear in the contraindication list. This is consistent with the traditional caution about triptans in aura subtypes with brainstem symptoms.
- Drug interactions: 82 interactions were identified. Major-level interactions include:
- lorcaserin
- dolasetron
- palonosetron
- ondansetron
- granisetron
- dexfenfluramine
- fenfluramine
- sibutramine
Most of these are serotonergic agents. Moderate-level interactions include morphine (including liposomal), cimetidine and obeticholic acid.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic argument is plausible, and zolmitriptan is already marketed in Australia for migraine. However, there are no clinical trials for brainstem aura, and none of the literature is specific to this subtype (evidence level L4). The vascular contraindication signals, including vertebrobasilar insufficiency, add to the safety uncertainty.
To proceed, the following is needed:
- Review of the TGA Product Information, including the approved indication and the warnings and contraindications for aura subtypes
- A targeted literature review and expert neurology input on triptan safety and efficacy in brainstem aura (basilar-type) migraine
- Mechanism of action data to support the mechanistic-link analysis
- If the hypothesis is pursued, a small, carefully designed clinical study with cardiovascular and cerebrovascular screening
- A drug interaction management plan, particularly for serotonergic co-medications
Other predictions from the same model run:
- For cluster headache, guidelines recommend triptans, including nasal or oral zolmitriptan. However, the zolmitriptan-specific trials are small or have uncertain status.
- These two indications may be better first candidates for further evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.